Docket No.: <u>102.174</u>

			B35	
NEF	71-79	TPQVPLRPM* (SEQ ID NO:270)	HLA-B35	non described
NEF	74-81	VPLRPMTY (SEQ ID NO:271)	HLA-B35	(1)
NEF	73-82	QVPLRPMTYK (SEQ ID NO:272)	HLA-A3- A11	(1)
Lipopeptides H	IV			
TT-GAG	77-85 Palm-K-GR QYIKANSKFIGITE RGR SLYNTVATL (SEQ ID NO:273)		HLA-A2.01	
TT-POL1		alm-K-GR QYIKANSKFIGITE RGR ILKEPVHGV	HLA-A2.01	
TT-POL2	Palm-K-GR QYIKANSKFIGITE RGR NPDI VIYQYMDDL (SEQ ID NO:275) multi-epitope Multi HLA			
TT-NEF	Palm-K-GR QYIKANSKFIGITE RGR FPVTP QVPLRPMTYK (SEQ ID NO:276) multi-epitope			
Auxiliary T per	otide			
Tetanic toxine	830-843	QYIKANSKFIGITE (SEQ ID NO:1)	HLA-DR, H-2 K ^b	

IN THE CLAIMS

Please amend claim 38 to read as follows:

(Amended) 38. A lipopeptide of claim 23 wherein the auxiliary T epitope is the 830-843 peptide of tetanic toxin with the sequence QYIKANSKFIGITE (SEQ ID NO:1).

REMARKS

In this Amendment, the specification and claims have been amended as presented hereinabove to reflect the insertion of SEQ ID NO: designators into the appropriate parts of the disclosure to identify the sequences as presented in the accompanying Sequence Listing, filed with this amendment.

No new matter has been added by the change to page 1, line 31 of the application as originally filed, as the addition of "(tetanus)" is the English language spelling of the French term "tetanic". Furthermore, the corrections on page 2, line 15, page 6, lines 14 and 23, and page 28, line 1, simply reflect corrections of the French style abbreviations into English style abbreviations for 'major histocompatibility complex